title: A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome.
abstract: Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients.
authors.affiliation: Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
authors.forename: H
authors.initials: H
authors.lastname: Blaszyk
authors.forename: A
authors.initials: A
authors.lastname: Hartmann
authors.forename: J M
authors.initials: JM
authors.lastname: Cunningham
authors.forename: D
authors.initials: D
authors.lastname: Schaid
authors.forename: L E
authors.initials: LE
authors.lastname: Wold
authors.forename: J S
authors.initials: JS
authors.lastname: Kovach
authors.forename: S S
authors.initials: SS
authors.lastname: Sommer
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D015331:Cohort Studies; D005500:Follow-Up Studies; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D009154:Mutation; D011379:Prognosis; D011446:Prospective Studies